Dr. Ellen Langemeijer studied Molecular and Cellular Biology at Vrije Universiteit Amsterdam, where she graduated in 1998. Upon graduation, she worked for six years at Biotech company Galapagos Genomics as scientist on diverse research projects, including the development of the patented adenoviral SilenceSelect knock-down library.
Langemeijer returned to the VU in 2005 for her PhD research in the Medicinal Chemistry research group supervised by Prof. Martine Smit. She investigated the oncomodulatory signaling by two virus-encoded G protein-coupled receptors (GPCRs), US28 and UL33. Subsequently, as post-doc at Leiden University, she studied functional selectivity of ligands for the adenosine receptors, also GPCRs.
In 2013, Langemeijer returned to the Department of Chemistry and Pharmaceutical Sciences (CPS) at Vrije Universiteit, joining Molecular and Computational Toxicology as project manager for SafeSciMET; an European Modular Education and Training Programme in Safety Sciences for Medicines, coordinated by Prof. Nico Vermeulen. From 2013 till 2018, Langemeijer was managing director of the research institute AIMMS (Amsterdam Institute for Molecules and Life Sciences).
As of 2018, she managed several EU projects, like the MSCA-ITN in3, short for Integrating In vitro and In silico tools for toxicological screening, coordinated by Prof. Paul Jennings.
As the C&FS EU Project manager Ellen is/has been involved in projects like EU-ToxRisk, RDT (JRC tender 2020-2022), RISKHUNT3R and VHP4Safety with Paul Jennings (MolTox), the MSCA-DN ONCORNET2.0 with Martine Smit (MedChem) and the HE-funded FREIA-project with Majorie van Duursen (Environment & Health, ALIFE).
